Background-Emerging evidence in obesity and diabetes mellitus demonstrates that excessive myocardial fatty acid uptake and oxidation contribute to cardiac dysfunction. Transgenic mice with cardiac-specific overexpression of the fatty acid-activated nuclear receptor peroxisome proliferator-activated receptor-␣ (myosin heavy chain [MHC]-PPAR␣ mice) exhibit phenotypic features of the diabetic heart, which are rescued by deletion of CD36, a fatty acid transporter, despite persistent activation of PPAR␣ gene targets involved in fatty acid oxidation. Methods and Results-To further define the source of fatty acid that leads to cardiomyopathy associated with lipid excess, we crossed MHC-PPAR␣ mice with mice deficient for cardiac lipoprotein lipase (hsLpLko). MHC-PPAR␣/hsLpLko mice exhibit improved cardiac function and reduced myocardial triglyceride content compared with MHC-PPAR␣ mice. Surprisingly, in contrast to MHC-PPAR␣/CD36ko mice, the activity of the cardiac PPAR␣ gene regulatory pathway is normalized in MHC-PPAR␣/hsLpLko mice, suggesting that PPAR␣ ligand activity exists in the lipoprotein particle. Indeed, LpL mediated hydrolysis of very-low-density lipoprotein activated PPAR␣ in cardiac myocytes in culture. The rescue of cardiac function in both models was associated with improved mitochondrial ultrastructure and reactivation of transcriptional regulators of mitochondrial function.
Clinical Perspective on p 435
Multiple mechanisms have been proposed to drive diabetes mellitus-associated heart dysfunction, including glucose toxicity (advanced glycation end products), 5 microvascular dis-ease, 6 mitochondrial dysfunction, 7, 8 and lipid toxicity. 9, 10 Evidence supports a role for lipid metabolic derangements in the development of cardiomyocyte dysfunction in the insulinresistant and diabetic heart 9, 10 ; both lipid accumulation and excessive fatty acid (FA) oxidation (FAO) are postulated to cause cardiomyocyte toxicity. Human studies and animal models demonstrate that diabetes mellitus and obesity are associated with accumulation of myocyte fat. 11, 12 Additionally, the insulin-resistant heart is unable to fully use glucose, forcing the organ to rely on FAs, leading to a vicious cycle of increased myocyte FA import, oxidation, and triglyceride accumulation, 10 signatures of a metabolic cardiomyopathy called lipotoxic cardiomyopathy.
Reprogramming of the insulin-resistant heart toward FA use involves gene regulatory mechanisms. Peroxisome proliferator-activated receptor-␣ (PPAR␣), a fasting-induced nuclear receptor, is chronically activated in the insulin-resistant and diabetic heart, 8, 13 coordinately upregulating genes involved in cellular FA uptake and oxidation. 14 PPAR␣ is a ligand-activated transcription factor, but the endogenous ligand(s) has not been fully determined. It is well established that FA moieties and fibrates activate PPARs. 15 Transgenic mice with cardiac-specific overexpression of PPAR␣ (myosin heavy chain [MHC]-PPAR␣ mice) exhibit a phenotype similar to that of the diabetic heart: ventricular dysfunction associated with increased FA uptake and FAO, myocyte triglyceride deposition, and reduced glucose use. 13 This cardiomyopathy of MHC-PPAR␣ mice is exacerbated by a high-fat (HF) diet, consistent with the importance of FA overload in driving lipotoxic effects.
FAs are delivered to cardiomyocytes from 2 major sources: albumin-bound free FA (FFA) released from adipose tissue and FA incorporated into triglycerides within very-lowdensity lipoprotein (VLDL) or from intestines within chylomicrons. Both FFA and lipoprotein-derived FA are substrates for human hearts via receptor-mediated uptake. Although there are several FA transporters, it is well established that CD36 mediates FFA uptake into rodent 16 and human hearts. 17 Previously, we crossed MHC-PPAR␣ mice with CD36deficient mice (MHC-PPAR␣/CD36ko). 18 CD36 deficiency prevented development of cardiomyopathy and myocardial triglyceride overload and normalized glucose oxidation rates in MHC-PPAR␣ hearts. 18 However, FAO rates and expression of PPAR␣ gene targets involved in FAO remained elevated in the MHC-PPAR␣/CD36ko mice, suggesting that PPAR␣ ligand was still being delivered to the MHC-PPAR␣ hearts.
Lipoprotein lipase (LpL) associated with the capillary endothelium is primarily responsible for liberation of triglyceride-derived FA. 19 Cardiac-specific deletion of this enzyme reduced heart lipoprotein-derived FA uptake without altering FFA uptake. 20 To further define the FA source that drives lipotoxic cardiomyopathy, MHC-PPAR␣ mice were crossed with heart-specific LpL knockout (hsLpLko) mice. 20 We found that LpL deficiency rescues the lipotoxic cardiomyopathy and reverses the chronic activation of PPAR␣, identifying a source of PPAR␣ ligand, which must be delivered via a CD36-independent pathway. Additionally, we found that the rescue of cardiomyopathy by either CD36 or LpL deficiency correlates with reactivation of genes involved in regulating mitochondrial function.
Methods

Animal Generation and Experiments
The generation of the MHC-PPAR␣/hsLpLko mice is described in the Methods section of the online-only Data Supplement. MHC-PPAR␣/CD36ko mice have been described elsewhere. 18 For HF diet studies, 1-month-old male and female mice were fed a diet with 43% calories from fat containing triglycerides composed of long-chain FA (TD01381, Harlan Teklad, Madison, Wis) for 4 weeks. All animal experiments were conducted in accordance with National Institutes of Health guidelines for humane treatment of animals and reviewed by the Animal Studies Committee of the Washington University School of Medicine.
Histological Analyses
Oil Red O staining was performed as described by the Morphology Core of the Digestive Diseases Research Core Center (DDRCC) at the Washington University School of Medicine. 18
Myocardial Triglyceride Quantification and Plasma Chemistries
Tissue triglyceride and serum FA, triglyceride, and cholesterol levels were determined by enzymatic, colorimetric assays (Thermo Scientific, Waltham, Mass, and Wako Pure Chemical Industries, Ltd. Osaka, Japan) by the Clinical Research Nutrition Unit Core at the Washington University School of Medicine.
Echocardiographic Studies
Transthoracic M-mode and 2-dimensional echocardiography was performed on conscious mice (nϭ3 to 4 males and 3 to 4 females per group) with an Acuson Sequoia 256 Echocardiography system (Acuson Corp, Mountain View, Calif) as described. 21
Electron Microscopy
Papillary muscle was dissected from the left ventricle (LV) of the heart, fixed as described, 22 and sectioned for electron microscopy.
RNA Isolation and Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction Analyses
Total RNA was isolated from male and female hearts (nϭ7 to 10 per group) and subjected to quantitative real-time reverse-transcription polymerase chain reaction (Q-rtPCR) using mouse-specific primerprobe sets as previously described. 8, 23, 24 
Mouse Isolated Working Heart Preparation
Low-expressing MHC-PPAR␣/hsLpLko animals were used for isolated working heart studies. Eight-week-old male and female mice (nϭ6 to 9 per group) on standard diet had isolated working heart preparations performed as described. 25 The Krebs-Henseleit perfusate solution contained 5 mmol/L glucose, 100 U/mL insulin, and 0.4mmol/L palmitate.
VLDL Uptake Studies
VLDL was isolated from normolipidemic human donors by ultracentrifugation at dϭ1.006 g/mL for 22 hours at 39 000 rpm and subjected to labeling as previously described. 26 Details of VLDL preparation and injection are given in the Methods section of the online-only Data Supplement.
Neonatal Rat Ventricular Myocyte Preparation
Neonatal rat ventricular myocytes (NRVMs) were isolated from 1-day-old Sprague-Dawley rat pups with a kit from Worthington Biochemical Corp (Lakewood, NJ). Cells were resuspended in medium (10% horse serum, 5% FCS, 100 mol/L BrdU, 2mmol/L L-glutamine in DMEM containing 4.5 g/L glucose).
Transient Transfection Assays
NRVMs were plated at a concentration of Ϸ3 000 000 cells/mL in 12-well gelatin-coated (Millipore, Billerica, Mass) plates. At the time of plating, cells were transfected with plasmid DNA using the calcium-phosphate method as described. 27 A detailed description of plasmid constructs and concentrations, reagents, and cell harvest can be found in the Materials section of the online-only Data Supplement. . Plasma levels of FFA, triglycerides, and cholesterol were not significantly different between any genotype after HF diet (Table I of the online-only Data Supplement). Although plasma triglyceride trended toward being higher in hsLpLko animals, it was not further altered in the setting of the MHC-PPAR␣ transgene.
Statistics
Results
LpL Deficiency Rescues Cardiomyopathy in MHC-PPAR␣ Mice
As expected, MHC-PPAR␣ mice exhibited increased LV mass index, reduced LV fractional shortening, and increased LV systolic and diastolic diameters ( Figure 1 and Table II of the online-only Data Supplement), a phenotype that worsened after the HF diet. In contrast, MHC-PPAR␣/hsLpLko mice had normal ventricular function, LV mass index, and chamber size on both diets. Thus, LpL is necessary for the development of cardiomyopathy in MHC-PPAR␣ mice.
LpL Deficiency Rescues the Myocardial Metabolic Derangements of MHC-PPAR␣ Mice
After 4 weeks of HF diet, Oil Red O staining, a marker of neutral lipid overload, demonstrated abnormal lipid accumulation in myocardial sections from MHC-PPAR␣ mice compared with WT controls (Figure 2A ). In striking contrast, lipid staining was similar in hearts from MHC-PPAR␣/ hsLpLko and WT mice. Consistent with these results, triglyceride levels in the hearts of MHC-PPAR␣ mice were 15-fold greater than those of WT controls but were normal in MHC-PPAR␣/hsLpLko hearts ( Figure 2B ).
To evaluate the effects of LpL deficiency on myocardial fuel use, we used an isolated working heart preparation. Low-expressing MHC-PPAR␣ mice 13 were chosen for these experiments because, in the absence of HF diet, this line does not develop ventricular dysfunction, which can independently influence myocardial substrate use rates. As previously shown, MHC-PPAR␣ mice exhibited high rates of palmitate oxidation and reduced glucose oxidation rates ( Figure 3 ). 13, 28 In striking contrast, myocardial glucose and palmitate oxidation rates of MHC-PPAR␣/hsLpLko mice were not different from those of WT animals, indicating a complete reversal of the cardiac fuel use abnormalities characteristic of MHC-PPAR␣ mice. Taken together with the results of the myocardial triglyceride measurements, these results indicate that cardiac-specific LpL deficiency corrects elevated myocardial triglyceride levels and fuel use derangements in MHC-PPAR␣ mice.
Rescue of the Cardiomyopathy Phenotype of MHC-PPAR␣ Mice Correlates With Normalization of Mitochondrial Ultrastructural Abnormalities
The above results, together with our previously published work, 18 demonstrate that the cardiomyopathy associated with MHC-PPAR␣ mice is rescued by either CD36 deficiency or LpL deficiency. The metabolic phenotypes of the 2 rescue models display both overlapping and distinct features, potentially providing a clue about the basis for lipotoxic forms of cardiomyopathy. In both cases, triglyceride accumulation is reversed, but only LpL deficiency reverses the high FAO rates driven by PPAR␣. These results suggest that triglyceride accumulation rather than increased FAO rates is linked to cardiac dysfunction. Recent data demonstrate an association between cellular lipid accumulation and mitochondrial dysfunction. 7, 8, 29 In addition, balanced fuel use requires appropriately matched mitochondrial capacity to oxidize fuels via the tricarboxylic acid cycle and oxidative phosphorylation pathways. 30 Evaluation of electron micrographs prepared from the LVs of MHC-PPAR␣ hearts demonstrated disorganized mitochondria with altered cristae density and architecture (black arrows in Figure 4A ). Increased mitochondrial volume density was also noted. These changes were strikingly absent in electron micrographs of MHC-PPAR␣/hsLpLko heart muscle ( Figure 4A ). The transcriptional coactivator PPAR␥ coactivator-1␣ (PGC-1␣) serves a critical role in controlling mitochondrial biogenesis and function in the postnatal heart. 22, 31, 32 The expression of PGC-1␣ is dysregulated in several mouse models of heart failure. 33, 34 We found that levels of PGC-1␣ messenger RNA were significantly reduced in the MHC-PPAR␣ hearts ( Figure 4B ). Both LpL deficiency and CD36 deficiency reversed the downregulation of PGC-1␣ expression ( Figure 4C ). Furthermore, the expression of additional genes involved in mitochondrial metabolism, including the tricarboxylic acid cycle (succinate dehydrogenase-␣) and oxidative phosphorylation (ATP synthase ␤), was reduced in hearts from MHC-PPAR␣ mice but normalized in MHC-PPAR␣/hsLpLko hearts ( Figure 4D ). Taken together, these data suggest that myocardial lipid accumulation leads to mitochondrial dysfunction related, at least in part, to suppression of PGC-1␣ gene expression.
LpL Is Required for the Delivery of PPAR␣ Ligand to the Cardiac Myocyte
LpL deficiency rescued both glucose and FA use abnormalities in MHC-PPAR␣ mice, unveiling a striking phenotypic difference compared with CD36 deficiency. Specifically, CD36 deficiency did not reverse the high FAO rates and the increased expression PPAR␣ FAO target genes in MHC-PPAR␣ hearts, indicating that PPAR␣ is still chronically stimulated in this model. 18 In contrast, cardiac expression of PPAR␣ target genes in the MHC-PPAR␣/hsLpLko mice was not different from that in WT mice. Specifically, the expression of PPAR␣ target genes involved in FAO (muscle-type carnitine palmitoyl-transferase-1, uncoupling protein 3, and acyl-coA oxidase), FA uptake (FA transport protein 1 [FATP1]), and glucose metabolism (pyruvate dehydrogenase kinase 4 and glucose transporter 4) in hearts from HF-fed MHC-PPAR␣/hsLpLko mice was normalized to the level in WT animals ( Figure 5 ). CD36 expression was not significantly different between genotypes ( Figure III of the online-only Data Supplement). PPAR␤ also plays a role in regulating cardiac metabolism, and we have found that the ratio of PPAR␣ to PPAR␤ drives lipid accumulation and cardiomyopathy. 35 Gene expression for PPAR␤ was mildly increased in MHC-PPAR␣ hearts (2.2-fold) but was unchanged in MHC-PPAR␣/hsLpLko hearts compared with WT hearts (data not shown).
The gene expression data demonstrating that LpL deficiency normalizes the expression of PPAR␣ metabolic gene targets suggest that LpL plays a more important role than CD36 in delivering FA or other PPAR␣ ligands to cardiomyocytes. To assess the impact on lipoprotein-derived FA uptake in the 2 models, radiolabeled lipid uptake studies were performed in WT, MHC-PPAR␣, MHC-PPAR␣/hsLpLko, and MHC-PPAR␣/CD36ko mice using double-labeled VLDL; triglycerides were labeled with 14 C; and cholesteryl ester (CE) was labeled with 3 H. Eight-to 10-week-old animals were injected with the dual-labeled VLDL, and tissue was harvested 30 minutes after injection. Cardiac uptake of 14 C-labeled triglycerides by MHC-PPAR␣ mouse hearts was increased compared with WT animals. Triglyceride-derived lipid uptake was normalized in both LpL-and CD36-deficient MHC-PPAR␣ mice ( Figure 6 ). In contrast, 3 H-CE uptake was dramatically reduced in LpL-deficient MHC-PPAR␣ mice but not in CD36-deficient hearts ( Figure 6 ). A similar reduction in CE uptake was seen in hsLpLko animals compared with WT animals (data not shown).
LpL-and CD36-deficient hearts differed in the uptake of "core lipids" that are not hydrolyzed and remain associated with the VLDL remnant. Thus, we postulated that the lipid contained in lipoprotein remnants activates PPAR␣ in heart and that the ligand enters the cardiomyocyte independently of CD36 in an LpL-dependent manner. To test this hypothesis, a cell culture assay was used in which the Gal4-PPAR␣-LBD fusion reporter was used in primary NRVMs. As expected, the FA oleate activated Gal4-PPAR␣-LBD to a modest (3-fold) but significant extent ( Figure 7A ). Docohexanoic acid (DHA) had an effect similar to that of oleate, but palmitate was unable to activate the Gal4-PPAR␣-LBD ( Figure V of the online-only Data Supplement). VLDL alone had no effect on Gal4-PPAR␣-LBD activation. However, in the presence of LpL, VLDL resulted in a striking 15-fold activation of Gal4-PPAR␣-LBD, consistent with the hypothesis that LpL is necessary for VLDL-mediated PPAR␣ activation. Studies done using higher concentrations of oleate resulted in a slight additional effect at 400 mol/L, but the VLDL/LpL effect was still much greater (data not shown). To assess the necessity of LpL enzymatic activity in VLDL activation of PPAR␣, the experiments were repeated using VLDL that had been depleted of triglycerides by pretreatment with LpL or in the presence of the LpL inhibitor tetrahydrolipostatin (THL). Both the triglyceride-depleted VLDL remnant (which contains core lipids) and VLDLϩTHLϩLpL were able to activate the reporter only to a level similar to oleate ( Figure 7B) . These results indicate that the mechanism whereby LpL increases PPAR␣ activation requires triglyceride lipolysis and intact LpL enzymatic activity.
Our results indicated that the LpL-mediated delivery of PPAR␣ ligand was CD36 independent. Thus, the NRVM experiments were repeated after "knockdown" of CD36. CD36 small interfering RNA (siCD36) reduced CD36 messenger RNA expression by Ͼ90% compared with cells transfected with control small interfering RNA (siCtrl) (Fig-ure IV of the online-only Data Supplement). NRVMs were transfected with either siCtrl or siCD36 in the presence of oleate or VLDL/LpL. Cells treated with oleate or VLDL/LpL and siCD36 had a visible decrease in intracellular lipid droplets compared with cells transfected with siCtrl, providing evidence for a reduction in CD36 function (data not shown). However, even in the presence of siCD36, oleate or VLDL/LpL activated the Gal4-PPAR␣-LBD ( Figure 7C ). These data are consistent with the in vivo data and strongly suggest that ligands generated by LpL-mediated hydrolysis of VLDL are transported into the myocyte independently of CD36.
Discussion
To understand the contributions of increased FA use and lipid accumulation to diabetic cardiac dysfunction, several transgenic mouse models have been generated, including cardiacspecific LpL, 36 acyl-CoA-synthetase and 37 FATP1 overexpression, 38 and the MHC-PPAR␣ model used in this study. 28 MHC-PPAR␣ mice reproduce the diabetic metabolic signatures of increased FAO and cardiac triglyceride stores combined with reduced glucose use. Characterization of these models has led to new questions relevant to the role of lipotoxicity in the development of cardiomyopathy including: What is the relative contribution of FAO and triglyceride accumulation to the cardiomyopathy? Why, despite greater FAO rates, do triglycerides accumulate in the myocyte? Finally, what is the source of excess lipid (FFA or lipoproteins), and does it also activate PPAR␣? We have previously shown that cardiac function can be restored in MHC-PPAR␣ mice bred into a CD36-deficient background. 18 CD36 deficiency reduces uptake of both FFA and lipoprotein-derived FA. The present study addressed the specific contribution of LpL to lipotoxic cardiomyopathy, when FA transporters remained intact. The study revealed 3 key findings: cardiac LpL deficiency rescues contractile dysfunction and myocardial triglyceride accumulation in MHC-PPAR␣ mice; lipoprotein-derived FA is a major source of lipid for this form of cardiomyopathy; and delivery of PPAR␣ ligand is dependent on LpL-mediated hydrolysis of VLDL and independent of CD36.
Many mechanisms have been proposed for cardiac dysfunction associated with excessive lipid uptake, including direct toxicity caused by FAs, triglycerides, or other lipids 39, 40 ; excessive FAO resulting in reactive oxygen species and/or increased oxygen consumption 39 ; decreased glucose oxidation; and altered mitochondrial function. 7, 8, 29 The current rescue with LpL deficiency is similar to our previous MHC-PPAR␣/CD36ko animals in the rescue of triglyceride accumulation, confirming that excess lipid contributes to contractile dysfunction. Correction of the lipotoxicity by LpL deletion is further proof that lipoprotein-triglycerides, and not FFA, is the primary culprit.
Our data also point to derangements in mitochondrial function, mediated by downregulation of PGC-1␣, as a potential determinant of cardiomyopathy in this lipotoxic model. Consistent with this notion, we found that LpL deficiency corrected the reduction in mitochondrial metabolic target gene expression and mitochondrial ultrastructural derangements in hearts of MHC-PPAR␣ mice. From these results, we speculate that myocyte lipid overload leads to reduced PGC-1␣ signaling, which in turn contributes to ventricular dysfunction in lipotoxic cardiomyopathy. The mechanism whereby PGC-1␣ gene expression is downregulated by cellular lipid overload is unknown but is likely a temporal phenomenon because, in insulin-resistant hearts, we have found that both PPAR␣ expression and PGC-1␣ expression are upregulated, 8 perhaps an adaptive response that fails once lipotoxic effects ensue. We have also found that PPAR␣ is capable of activating the PGC-1␣ promoter in certain cell types (J.G.D. and D.P.K., unpublished data), suggesting that an autoregulatory loop exists between PPAR␣ and its coactivator PGC-1␣. We suspect that lipid overload, combined with PPAR␣ activation, results in downregulation of PGC-1␣ via mechanisms that have not been delineated. Our present data cannot exclude a contribution of reduced myocardial glucose oxidation to contractile dysfunction because both CD36 deficiency and LpL deficiency normalized glucose oxidation rates in MHC-PPAR␣ mice. However, in another model of cardiac lipotoxicity (MHC-PPAR␥), glucose uptake is not altered. 41 A novel finding in this study was that LpL deficiency reversed the excess FAO and chronic activation of PPAR␣ gene targets involved in FAO. This observation contrasts with CD36 deficiency, which did not affect activation of PPAR␣ targets or FAO in MHC-PPAR␣ mice. 18 These results identify a fundamental difference in the pathways involved in the delivery and generation of ligand for PPAR␣ in the heart.
Because CD36 reduces uptake of both FFA and lipoproteintriglycerides, the reduction in total FA uptake should be greater in MCH-PPAR␣/CD36ko; our data implicate a ligand other than FFA in PPAR␣ activation. Previous in vitro studies have shown that VLDL/LpL can activate PPARs in endothelial cells and macrophages. [42] [43] [44] Our data extend these findings to an in vivo model and suggest that myocardial LpL participates in PPAR␣ ligand generation. NRVM studies confirmed that VLDL, in the presence of LpL, leads to robust activation of a PPAR␣ reporter. Furthermore, activation of PPAR␣ by VLDL/LpL or oleate occurs in the absence of CD36, confirming that the ligand delivery pathway is independent of CD36. It is possible that mechanisms such as diffusion 45 or alternative transporters (eg, FATP family members) are important for transporting and targeting PPAR␣ ligand in the CD36-deficient animals. Notably, LpL deficiency does not eliminate PPAR␣ activation, reflected by target gene expression and FAO rates similar to those of WT, suggesting that some ligand is available for basal PPAR␣ activation. In addition, the lipid uptake studies demonstrate that MHC-PPAR␣/hsLpLko animals have triglyceride uptake similar to WT, suggesting that basal VLDL-triglyceride uptake is preserved. This may occur via several mechanisms, including noncardiomyocyte LpL activity (eg, macrophages), 46 peripheral lipolysis leading to FA uptake by non-LpL-mediated pathways, or uptake of VLDL "remnant" lipoproteins generated via peripheral lipolysis.
The specific cardiac PPAR␣ ligand was not defined in this study, but several clues were provided. The VLDL uptake studies performed in vivo revealed a dramatic difference in CE uptake between CD36-deficient and LpL-deficient MHC-PPAR␣ animals. CE is a marker of whole particle uptake, suggesting that the ligand activity could reside in lipid moieties other than triglyceride-derived FA. However, the NRVM experiments using triglyceride-depleted VLDL demonstrated a decreased ability to activate the PPAR␣-LBD, suggesting that triglyceride lipolysis is necessary for the full PPAR␣-activating effect; providing remnant-like lipoproteins to the cells alone is not sufficient. These latter results are consistent with previous findings suggesting that intact LpL enzymatic activity was necessary for PPAR␣ activation. 43 Ligand generation from VLDL particle components may be a multistep process requiring triglyceride hydrolysis and components of the core lipid. LpL hydrolysis results in the elaboration of a number of other lipid species, including oxidized lipids (eg, HODEs 47 ) that could activate PPAR␣. It should also be noted that we have not excluded the possibility that activating ligand(s) for related PPARs (PPAR␦, PPAR␥) may be carried by the VLDL particle. Further studies are warranted to evaluate the specific components of VLDL lipolysate that are capable of activating PPAR␣ and their downstream effect on the cardiomyocyte. Identification of the specific PPAR␣ ligand could lead to tissue-specific strategies to block chronic activation of the cardiac PPAR␣ pathway and thus preventive or therapeutic strategies for lipotoxic cardiomyopathy in humans.
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